Ultragenyx Pharmaceutical IncUltragenyx Pharmaceutical Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Detailed Sustainability analysis of Ultragenyx Pharmaceutical Inc can be reached by signing in. Alternative corporations in the scoring peer group for Ultragenyx Pharmaceutical Inc are displayed. The Disclosure rating includes seventeen United Nations SDGs including: 'No Poverty', 'Climate Action' and 'Partnerships for the Goals'.

Ultragenyx Pharmaceutical Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.2; made up of an environmental score of 8.0, social score of 6.9 and governance score of 6.7.

SDG Transparency Score for Ultragenyx Pharmaceutical Inc 
Low
0 - 3
Medium
4 - 6

7.2

High Impact
7 - 10
Last Score Update: 2024-05-01
What drives the score for Ultragenyx Pharmaceutical Inc 
8.0

Environmental

6.9

Social

6.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
191Wockhardt Ltd
7.3
High
191Zealand Pharma A/S
7.3
High
217Ultragenyx Pharmaceutical Inc
7.2
High
217Eurofins Scientific SE
7.2
High
217Dermapharm Holding SE
7.2
High
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Ultragenyx Pharmaceutical Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc offer flexible work?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose water use targets?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Ultragenyx Pharmaceutical Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Ultragenyx Pharmaceutical Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Ultragenyx Pharmaceutical Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose its waste policy?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose energy use targets?

LockedSign up for free to unlock

Does Ultragenyx Pharmaceutical Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Ultragenyx Pharmaceutical Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Ultragenyx Pharmaceutical Inc
These potential risks are based on the size, segment and geographies of the company.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Sorry!

Failed to process!